Cathie Wood stocks have been foundering for the past few months owing to volatile market conditions caused in-part by aggressive Federal Reserve interest rate hikes. So, given their companies’ bleak...
Telemedicine has a sizable growth runway ahead.
They present very different kinds of bargains.
An analyst bucks the trend and lifts her price target on the stock.
Once prosperous investments throughout the pandemic, the high-flying days for these stocks is well over in 2022.
A rebound could be on the horizon.
While there's no hiding from a tough first quarter, user metrics remained solid.
Here's why this deal makes sense.
Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.
Teladoc Health's (TDOC) bet on mental health service BetterHelp is likely to generate lower yield this year.